This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
18, 2024 — Abbott recently announced new data for the Amplatzer Amulet Left Atrial Appendage (LAA) Occluder to treat people with atrial fibrillation (AFib) who are at an increased risk of stroke. Kansas City HeartRhythm Institute at HCA Midwest Health, who served as principal investigator for the Amulet IDE trial.
mtaschetta-millane Tue, 07/16/2024 - 09:47 July 16, 2024 — Ultrahuman, a pioneer in wearable technology , launches PowerPlugs, a platform for individual apps and plugins built on top of Ultrahuman’s health and wellness data stack. Ultrahuman Ring AIR is the first smart ring in the world to offer AFib detection.
16, 2025 Primary results from the DEFINE AFib clinical study show the Medtronic LINQ family of insertable cardiac monitors (ICM), paired with a novel algorithm, were able to detect atrial fibrillation episodes and properly risk stratify patients as high risk prior to an AF-related healthcare utilization 80% of the time. Piccini, M.D.,
In the age of technology, wearable devices have revolutionized how we approach health and wellness. Among their many benefits, wearable tech has proven to be a game-changer in monitoring heart health, particularly for individuals managing cardiovascular conditions or preparing for minimally invasive or bloodless heart surgery.
Atrial fibrillation (AFib) is a common heartrhythm disorder characterized by an irregular and often rapid heartbeat. This condition can lead to various complications, including stroke and heart failure, making it essential to understand its causes, symptoms, and AFib treatment options. What is Atrial Fibrillation?
Innovation in medical technology exists to improve patient outcomes, increase surgical efficiency and enhance patient safety. Infrequently, we see medical technology innovation of a paradigmatic nature that changes the way physicians approach disease states and dramatically improve results.
The results support the use of workflows to reduce radiation exposure during catheter ablation for the treatment of paroxysmal atrial fibrillation (AFib) while maintaining safety, efficacy, and long-term patient outcomes comparable to traditional procedures.1 1 These included one pseudoaneurysm, one PV stenosis and one hematoma.1
In a world where technology reigns supreme, one of the most profound tools in medicine remains the irreplaceable electrocardiogram (ECG). It can measure many aspects, from how fast the heart beats to how well its chambers conduct electrical energy. Sinus tachycardia – sinus rhythm above 100 bpm is a sinus tachycardia.
During its Annual Conference, HRS 2024, the HeartRhythm Society (HRS) announced findings from three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrial fibrillation (AF). See full findings from the FARADISE, admIRE Study, and Advent Trial here.
tim.hodson Thu, 03/27/2025 - 12:18 March 27, 2025 Abbott recently announced it has received CE Mark in Europe for the Volt PFA System to treat patients battling atrial fibrillation (AFib). Today, approximately 8 million Europeans over the age of 65 are living with AFib, a number expected to double over the next 30 years.
milla1cf Wed, 12/13/2023 - 10:24 December 13, 2023 — A new artificial intelligence (AI) model designed by Scripps Research scientists could help clinicians better screen patients for atrial fibrillation (or AFib)—an irregular, fast heartbeat that is associated with stroke and heart failure.
Volta Medical has announced it has entered into a Joint Development Agreement with GE Healthcare to enhance arrhythmia procedures with artificial intelligence (AI)-driven electrophysiology technologies. Our mission to combat complex heartrhythm diseases relies on optimizing interoperability.
Four heartrhythm organizations from around the globe developed the statement. It is also published in HeartRhythm , the official journal of the HRS, Journal of Arrhythmia , the official journal of the APHRS, and Journal of Interventional Cardiac Electrophysiology , the official journal of the LAHRS.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content